KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Equity Average (2016 - 2025)

Arbutus Biopharma's Equity Average history spans 14 years, with the latest figure at $80.2 million for Q3 2025.

  • For Q3 2025, Equity Average fell 30.07% year-over-year to $80.2 million; the TTM value through Sep 2025 reached $80.2 million, down 30.07%, while the annual FY2024 figure was $101.7 million, 16.26% down from the prior year.
  • Equity Average for Q3 2025 was $80.2 million at Arbutus Biopharma, down from $81.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $167.6 million in Q1 2022 and bottomed at $80.2 million in Q3 2025.
  • The 5-year median for Equity Average is $115.5 million (2021), against an average of $121.7 million.
  • The largest annual shift saw Equity Average soared 55.14% in 2022 before it crashed 31.62% in 2025.
  • A 5-year view of Equity Average shows it stood at $149.8 million in 2021, then decreased by 5.74% to $141.2 million in 2022, then decreased by 20.19% to $112.7 million in 2023, then dropped by 9.36% to $102.1 million in 2024, then dropped by 21.48% to $80.2 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Equity Average are $80.2 million (Q3 2025), $81.1 million (Q2 2025), and $88.3 million (Q1 2025).